Cardinal Health and Stryker are Dominating the Market for Global Transradial Access in 2017

Global Transradial Access Market is expected to reach USD 2,061.79 Million by 2025 from USD 1,105.79 Million in 2017, at a CAGR of 8.2% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Access Full Report@

The global transradial access market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Cardinal Health dominates transradial access market, accounting for the highest market share in 2017, followed by Stryker and Angiodynamics Inc. Other players in this market include BD, Terumo Corporation, Teleflex Incorporated, Smiths Group plc, MEDTRONIC, Boston Scientific Corporation, Edwards Lifesciences Corporation, Merit Medical Systems Inc., NIPRO CORPORATION, Amecath, OSCOR Inc. and Penumbra among others holds 7.8% of the global transradial access system market in 2017.

Cardinal Health:

Cardinal Health was founded in 1979 and headquartered at Ohio, U.S. The company offers its integrated healthcare services and products to hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide.

The company operates through two business segments–medical segment and pharmaceutical segment. Medical business segment manufactures and distributes medical, surgical and laboratory products including cardiovascular and endovascular products, wound care products, single-use surgical drapes, gowns and apparel, exam and surgical gloves, and fluid suction and collection systems. In 2015, Cardinal Health acquired Cordis business of Johnson & Johnson for their cardiovascular and endovascular product portfolio. All transradial access products including guidewire, catheters fall under cardiovascular segment.

The company has its network in more than 60 countries worldwide including U.S., Australia, Japan, Canada, China, Puerto Rico and other Europe, Middle East, Africa countries. Some of company’s subsidiaries are Cordis Corporation (U.S.), RGH Enterprises, Inc. (U.S.), Source Medical Corp (Canada), CareFusion (U.S.), Medicine Shoppe International, Inc (U.S.), Viasys Healthcare (U.S.), Tecomet, Inc (U.S.) among others.

Recent Developments:

In October, 2015, Cardinal Health completed the acquisition of Johnson & Johnson's Cordis business for cardiology and endovascular devices. This acquisition enhanced the Cardinal Health product portfolio by offering products in the cardiovascular, wound management, and orthopedics segment.


Established in 1941 and headquartered at Michigan, U.S. Stryker is a one of the leading medical technologies company. The company provides products through three business segment Neurotechnology and Spine, MedSurg and Orthopaedics. The Neurotechnology and Spine segment offering include products related to neurotechnology. These are utilized in minimally invasive endovascular procedures, minimally invasive products for hemorrhagic stroke and acute ischemic treatment,   biosurgery and orthobiologic products such as vertebral augmentation and synthetic bone grafts products and others. Its products are identified on the web site in accordance with 35 U.S.C. § 287(a) by relating each known product with one or more patents.

Stryker sells its product and services in Canada, Asia, Europe, Eastern Europe, Middle East and Africa through its subsidiaries. Some of its subsidiaries are Physio-Control (U.S.), novadaq (Canada), howmedica osteonics (U.S.), MAKO Surgical (U.S.), Patient Safety Technologies (U.S.), Stryker Trauma GmbH (Germany), Stryker Biotech LLC (U.S.), Benoist Girard SAS (France), Howmedica International S. de R.L. (Ireland), Spinecore Inc. (U.S.) and others.

Recent Developments:

In October, 2010, Stryker Corporation entered into an agreement to acquire the assets of the Neurovascular division of Boston Scientific (U.S.) in an all cash transaction for USD 1.5 billion. This acquisition is a very important strategic move and will strengthen company’s space in neurovascular portfolio.

Angiodynamics Inc.-

Angiodynamics Inc. was founded in 1988 and headquartered at New York, U.S. The company is engaged in manufacturing and marketing of medical devices for vascular access, peripheral vascular disease, oncology and surgical settings. The company has three global operational business segments- vascular access, peripheral vascular products, oncology / surgery. Transradial access products such as guidewires and catheters are offered by vascular access as well as peripheral vascular products. Its manufacturing facilities are FDA registered, certified with ISO 13485 standards and CMD/CAS Canadian Medical Device in European Union countries. The company has its network in the United States, Europe and Asia. It sells products in more than 50 markets through direct sales and distributors. Few subsidiaries of Angiodynamics Inc are Navilyst Medical (U.S.), Microsulis Medical Limited (U.K.), Clinical Devices, B.V (Netherlands), Leocor, Inc (Germany), Vortex Medical, Inc (U.S.), RITA Medical Systems LLC (U.S), oncobionic (U.S.) among others.

BD (Becton, Dickinson and Company) -

BD (Becton, Dickinson and Company) was incorporated in 1906 and headquartered at New Jersey, U.S. The company is a leading medical technology company. It is engaged in manufacturing and marketing of wide range of medical devices, laboratory equipment, products and others. These products and devices are utilized by life science researchers, clinical laboratories, healthcare institutions, the pharmaceutical industry and the general public. The company offers innovative solutions in the area of advance medical research and genomics, in the diagnosis of infectious disease and cancer, equip surgical and interventional procedures.

The company operates its business through two business segments- BD Medical and BD Life Science. BD Medical offers products for diabetes care, medication management solutions, medication & procedural solutions and pharmaceutical systems. BD Life Science provides products for biosciences, diagnostic systems and preanalytical systems. Needles, syringes and intravenous catheters for drug delivery, IV catheters all come under the business segment BD Medical.

In 2017 BD acquired C.R. Bard (U.S.), a company which is engaged in the development, manufacturing and marketing of medical technologies. C.R. Bard offers wide range of peripheral products.

The company has its global presence in North America, South America, Europe, Asia Pacific and Middle East and Africa. It has strong network of subsidiaries such as CareFusion (U.S.), Accuri Cytometers Inc. (U.S.), Nippon Becton Dickinson Company, Ltd. (Japan), Becton Dickinson Private ltd. (India), PreAnalytiX GmbH (Switzerland) and others.

Recent Developments:

  1. In In December, 2017, BD acquired C.R. Bard (U.S.), a company engaged in the development, manufacturing and marketing of medical technologies. With this acquisition BD took over bard’s strong product portfolio and innovative pipeline in fast-growing clinical areas. This combination enhanced company’s presence in non-U.S. markets.